VG Life Sciences Inc. (VGLS) presents a deeply negative liquidation posture as of September 30, 2015. Under the liquidation lens, recoverable assets are approximately $40,300 (cash $22,919 at 100% plus prepaid/other current assets $17,407 at roughly 90-95%, yielding ~$39,000). Property and equipment is zero. Intangible assets of $1,076,836 — representing patent license rights under the Scott & White Healthcare agreement — receive a 0% recovery haircut under the liquidation framework, as these pre-commercial pharma licenses have no standalone third-party market value, particularly given the agreement was already terminated once for non-payment in early 2015 before being reinstated in May 2015 for a $45,000 cure payment. Total liquidation-recoverable assets are therefore approximately $40,000 against total current liabilities at face value of $5,461,663, producing an estimated equity recovery of roughly negative $5.4 million, consistent with the MFFAIS CLV/LLV/OLV figure of -$5,438,744. The liability stack is dominated by convertible debt: related-party convertible debt of $2,146,679 (owed to MedBridge Venture Fund and related entities controlled by the CEO and CFO) and third-party convertible debt of $1,237,882. Derivative liabilities of $940,040 — bifurcated embedded conversion features on variable-rate convertible notes — stay at face value in liquidation and have increased from $658,141 at December 31, 2014, adding approximately $282,000 to the liability stack since year-end. Accounts payable of $836,975 has grown from $710,349, reflecting ongoing vendor accruals with no cash to settle them. Cash on hand is $22,919, down from $33,992 at December 31, 2014, and the company disclosed post-period that these funds had already been utilized. Net cash used in operations was $450,924 for the nine months, offset by $439,851 in financing proceeds (primarily new convertible debt draws). Zero revenue has been generated in the current or any prior period. Accumulated deficit stands at $109,843,033. The going concern qualification is explicit. No PP&E exists. The sole non-cash asset of book value — the intangible — is an exclusive patent license in early-stage clinical/preclinical research with no commercialization timeline and a history of missed maintenance payments. The filing discusses patent license minimum annual obligations ($87,500 due January 2016, escalating to $250,000 annually from 2018 onward) and milestone payments (up to $2,000,000 per regulatory approval) in the MD&A and Note 6 commitments section, but these future obligations are not separately tagged in XBRL and do not appear as balance sheet liabilities. Their existence as contingent obligations further erodes any residual recovery optionality. Compared to the prior filing (Q2 2015, period ending June 30, 2015), the balance sheet structure is materially unchanged: liabilities decreased modestly as debt conversions into equity outpaced new borrowings, but the derivative liability increased by approximately $282,000 and accounts payable increased by $127,000. The share count increased from 46.2 million at December 31, 2014 to 101.5 million at September 30, 2015, reflecting the ongoing equity-for-debt conversion mechanism that is the company's primary liability management tool. This dilution does not affect the liquidation recovery calculation but signals the structural dependence on insider-controlled financing entities (MedBridge Development Company and MedBridge Venture Fund, both controlled by the CEO and CFO) to sustain operations.
▼ Community Notes